Ardelyx, Inc. (ARDX) News
Filter ARDX News Items
ARDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARDX News Highlights
- For ARDX, its 30 day story count is now at 5.
- Over the past 22 days, the trend for ARDX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ARDX are AERI.
Latest ARDX News From Around the Web
Below are the latest news stories about Ardelyx Inc that investors may wish to consider to help them evaluate ARDX as an investment opportunity.
Aerie Pharmaceuticals (AERI) Tops Q4 Earnings and Revenue EstimatesAerie (AERI) delivered earnings and revenue surprises of 260.29% and 272.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital PartnersArdelyx, Inc. (Nasdaq:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners ("SLR"). |
Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Monday February 28, at 4:30 pm Eastern Time to discuss fourth quarter and year-end 2021 financial results and provide a corporate update. |
Ardelyx, Inc. Reports Employment Inducement GrantsArdelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on February 1, 2022, the compensation committee of the company's board of directors granted four new non-executive employees options to purchase an aggregate of 35,547 shares of the company's common stock, and granted an aggregate of 25,750 Restricted Stock Units (RSUs) to five n |
Clarius Group, LLC Buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ...Investment company Clarius Group, LLC (Current Portfolio) buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ETF, Vanguard FTSE Emerging Markets ETF, iShares Core U.S. |
Waller Financial Planning Group, Inc Buys SPDR Portfolio Emerging Markets ETF, Vanguard ...Investment company Waller Financial Planning Group, Inc (Current Portfolio) buys SPDR Portfolio Emerging Markets ETF, Vanguard Intermediate-Term Bond ETF, Ardelyx Inc, sells Vanguard Short-Term Government Bond ETF, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Waller Financial Planning Group, Inc. |
With drug launch plan, East Bay company pivots back to the start after FDA rejectionThe company's drug was rejected this summer for one condition, so it plans to launch in the second quarter in another condition. |
Are Options Traders Betting on a Big Move in Ardelyx (ARDX) Stock?Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately. |
Analysts Predict An Ardelyx Inc. (NASDAQ: ARDX) Spike?Ardelyx Inc. (NASDAQ:ARDX) shares, rose in value on Thursday, 12/16/21, with the stock price up by 0.83% to the previous day’s close as strong demand from buyers drove the stock to $1.21. Actively observing the price movement in the last trading, the stock closed the session at $1.20, falling within a range of $1.1622 and … Analysts Predict An Ardelyx Inc. (NASDAQ: ARDX) Spike? Read More » |
Thinking about buying stock in Lucid Group, Energy Transfer, Ardelyx, Inspira Technologies, or Arbutus Biopharma?NEW YORK , Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, ET, ARDX, IINN, and ABUS. Full story available on Benzinga.com |